Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
506U78 in Treating Patients With Lymphoma
This study is no longer recruiting patients.
Sponsored by: | National Cancer Institute (NCI) Cancer and Leukemia Group B
|
---|---|
Information provided by: | National Cancer Institute (NCI) |
Purpose
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 506U78 in treating patients who have lymphoma that has not been treated previously or that has not responded to previous treatment.
Condition | Treatment or Intervention | Phase |
---|---|---|
Leukemia Lymphoma |
Drug: U78 |
Phase II |
MedlinePlus related topics: Leukemia, Adult Acute; Leukemia, Adult Chronic; Leukemia, Childhood; Lymphoma
Study Type: Interventional
Study Design: Treatment
Official Title: Phase II Study of 506U78 in Patients With Previously Systemically Untreated Cutaneous T-Cell Lymphoma or Refractory or Relapsed Noncutaneous Peripheral T-Cell Lymphoma
Study start: May 2000
OBJECTIVES: I. Determine the complete and partial remission rates and remission duration in patients with previously systemically untreated cutaneous T-cell lymphoma or refractory or relapsed noncutaneous peripheral T-cell lymphoma treated with 506U78. II. Determine the safety and toxicity of this treatment regimen in this patient population.
PROTOCOL OUTLINE: Patients are stratified according to diagnosis (cutaneous T-cell lymphoma vs peripheral T-cell lymphoma). Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving complete response receive up to a maximum of 8 courses of therapy. Patients are followed every 3 months for 1 year, and then every 6 months for 1 year or until relapse.
PROJECTED ACCRUAL: A total of 34-74 patients will be accrued for this study within 3 years.
Eligibility
Ages Eligible for Study: up to 69 Years
Criteria
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
--Prior/Concurrent Therapy--
--Patient Characteristics--
Location Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |